Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
|Articles|March 9, 2011
- December 2010
- Volume 4
- Issue 12
Effects of UV Radiation Are Cumulative
Author(s)OBTN
An article in Oncogene further explains how ultraviolet (UV) radiation helps transform skin cells into basal cell carcinoma.
Advertisement
An article in Oncogene further explains how ultraviolet (UV) radiation helps transform skin cells into basal cell carcinoma. Cells exposed to UV radiation ramp up production of protein kinase D, an enzyme that helps cells survive. The effect is cumulative: more exposure causes more protein kinase D expression, increasing the likelihood that DNA damaged skin cells survive and replicate. Pretreating skin cells with antioxidants reduced protein kinase D activation, suggesting that free radicals also contribute to skin cancer development.
Articles in this issue
over 15 years ago
Medulloblastoma Subtypes Are Different Diseasesover 15 years ago
ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myelomaover 15 years ago
FDA Requests Label Change for Generic DocetaxelAdvertisement
Related to this article
Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.
Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5